Nuclear Medicine Imaging Tools in Fever of Unknown Origin (FUO): Time for a Revisit and Appropriate Use Criteria.
William F WrightSheetal KandiahRebecca BradyBarry L ShulkinChristopher J PalestroSanjay K JainPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Fever of unknown origin (FUO) is a clinical conundrum for patients and clinicians alike and imaging studies are often performed as part of the diagnostic workup of these patients. Recently, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) convened and approved a guideline on the use of nuclear medicine tools for FUO. The guidelines support the use of 2-18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) in adults and children with FUO. 18F-FDG PET/CT allows the detection and localization of foci of hypermetabolic lesions with high sensitivity, based on 18F-FDG uptake in glycolytically active cells that may represent inflammation, infection, or neoplasia. Clinicians should consider and insurers should cover 18F-FDG PET/CT when evaluating patients with FUO, particularly when other clinical clues and preliminary studies are unrevealing.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- end stage renal disease
- pet imaging
- ejection fraction
- chronic kidney disease
- newly diagnosed
- magnetic resonance imaging
- dual energy
- high resolution
- palliative care
- image quality
- peritoneal dialysis
- young adults
- high grade
- photodynamic therapy
- patient reported outcomes
- oxidative stress
- magnetic resonance
- prognostic factors
- patient reported
- cell death
- fluorescence imaging
- pi k akt